MediciNova, Inc.
MNOV
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophicā¦ read more
Healthcare
Biotechnology
19 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.33
Price-0.75%
-$0.01
1Y
Price
Market Cap
$65.464m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-2435.4%
EBITDA Margin-2473.5%
Net Profit Margin-1383.5%
Free Cash Flow Margin-2435.4%
EBITDA Margin-2473.5%
Net Profit Margin-1383.5%
Free Cash Flow MarginRevenue
$596.640k
-
1y CAGR-33.3%
3y CAGR-50.0%
5y CAGREarnings
-$11.720m
-8.7%
1y CAGR+0.5%
3y CAGR-9.3%
5y CAGREPS
-$0.23
-4.3%
1y CAGR+0.6%
3y CAGR-9.1%
5y CAGRBook Value
$39.407m
$42.705m
Assets$3.298m
Liabilities$165.200k
DebtDebt to Assets
0.4%
-
Debt to EBITDAFree Cash Flow
-$9.507m
+8.6%
1y CAGR+2.7%
3y CAGR-7.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company